The other major pitfall in MM MRD evaluation by NGF is correlated to the high heterogeneity of MM plasma cells phenotype, and to the possibility of a “shift” of plasma cells phenotype depending on the therapy that patients have been exposed (64, 65).. The gene discussed is NGF; the disease is Miyoshi myopathy.